Clinical Trial

Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 6, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this clinical trial is to investigate the impact of Bifidobacterium longum(BL) on the clinical prognosis of patients with acute pancreatitis(AP), to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL. Participants will be randomly assigned to two groups: the intervention group and the control group. They will receive: * Intervention group: Standard clinical treatment + BL capsules (10\^10 CFU), twice a day, for a total of 14 days; * Control group: Standard clinical treatment + placebo capsules, for a total of 14 days. A total of 60 patients will be included in this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-10.
Trial Details
NCT Number NCT06639516
Lead Sponsor The First Affiliated Hospital of Nanchang University
Conditions Acute Pancreatitis
Enrollment 60 participants
Start Date 2025-02-15
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-06